Observational studyInternational journal of chronic obstructive pulmonary disease2013
Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease.
Observational study in International journal of chronic obstructive pulmonary disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Nocturia Work Productivity and Activity Impairment Compared with Other Common Chronic Diseases.PharmacoEconomics · 2016Pooled it
- A Systematic Literature Review of the Humanistic Burden of COPD.International journal of chronic obstructive pulmonary diseasePooled it
- Age-differentiated comparison of health-related quality of life and impacting factors in patients with COPD receiving long-term home non-invasive ventilation.BMC pulmonary medicine · 2025Observational
- Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET.Respirology (Carlton, Vic.) · 2025Observational
- An Italian Delphi Consensus on the Triple inhalation Therapy in Chronic Obstructive Pulmonary Disease.Multidisciplinary respiratory medicine · 2024Article
- Cost-effectiveness of population-based screening for chronic obstructive pulmonary disease in China: a simulation modeling study.The Lancet regional health. Western Pacific · 2024Article
- Differences in cardiovascular risk and health-related quality of life in COPD patients according to clinical phenotype.Scientific reports · 2024Observational
- An Applicable Framework for Understanding Successful Aging of People Living with HIV and Comorbid Chronic Obstructive Pulmonary Disease.Nursing (Auckland, N.Z.) · 2024Article
- 30-Day Readmission Rate of Patients with COPD and Its Associated Factors: A Retrospective Cohort Study from a Tertiary Care Hospital.International journal of chronic obstructive pulmonary disease · 2023Article
- Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice-The "AIOLOS" Study.Canadian respiratory journal · 2021Observational
- The Association of Low Income and High Stress with Acute Care Use in COPD Patients.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2020Article
- Management of chronic obstructive pulmonary disease: A review focusing on exacerbations.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2020Review
- Responsiveness of PROMIS® to change in chronic obstructive pulmonary disease.Journal of patient-reported outcomes · 2019Article
- Combining Nonclinical Determinants of Health and Clinical Data for Research and Evaluation: Rapid Review.JMIR public health and surveillance · 2019Review
- Severity of Airflow Obstruction and Work Loss in a Nationwide Population of Working Age.Scientific reports · 2018Article
- Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN Studies.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2018Article
- An analysis of the economic and patient outcome impact of an integrated COPD service in east London.International journal of chronic obstructive pulmonary disease · 2017Article
- COPD symptom burden: impact on health care resource utilization, and work and activity impairment.International journal of chronic obstructive pulmonary disease · 2017Article
- Impact and prevention of severe exacerbations of COPD: a review of the evidence.International journal of chronic obstructive pulmonary disease · 2017Review
- Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK.ClinicoEconomics and outcomes research : CEOR · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeExacerbation-associated health-related quality of life (HRQoL) in patients with severe and very severe chronic obstructive pulmonary disease (COPD) is ill-defined. This study describes patterns, HRQoL, and the work productivity impact of COPD-related moderate and SEV exacerbations in patients with SEV/VSEV COPD, focusing on the chronic bronchitis subtype. PATIENTS AND
methodsA US sample of SEV and VSEV COPD patients with recent moderate or SEV exacerbation was recruited. Along with the demographic and clinical data collected from medical records, patients reported on exacerbation frequency, health-related quality of life (HRQoL) (using the St George's Respiratory Questionnaire for COPD [SGRQ-C] and the European Quality of Life-5 Dimensions [EQ-5D]™ index), and work productivity and activity impairment (using the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem [WPAI-SHP]). The HRQoL-related impacts of exacerbation frequency, time since exacerbation, and last exacerbation severity were evaluated via linear regressions.
resultsA total of 314 patients (190 SEV/124 VSEV, mean age =68.0 years, 51% male, 28% current smokers) were included. In the previous 12 months, patients reported an average of 1.8 moderate exacerbations and 0.9 SEV exacerbations. Overall, 16% of patients were employed and reported a high percentage of overall work impairment (42.4% ± 31.1%). Activity impairment was positively associated with recent exacerbation severity (SEV 64.6% ± 26.8% versus moderate 55.6% ± 28.2%) (P=0.006). The HRQoL was significantly worse for SEV versus VSEV COPD (EQ-5D: 0.62 ± 0.23 versus 0.70 ± 0.17, respectively, and SGRQ-C: 70.1 ± 21.3 versus 61.1 ± 19.0, respectively) (P<0.001). Worse current HRQoL was reported by patients with a SEV versus moderate recent exacerbation (EQ-5D: 0.63 ± 0.21 versus 0.70 ± 0.20, respectively) (P=0.003); SGRQ-C: 70.3 ± 19.9 versus 61.7 ± 20.1, respectively (P<0.001). One additional exacerbation in the previous 12 months was associated with a 2.4-point SGRQ-C increase and a 0.02-point EQ-5D index decrease.
conclusionThe severity and frequency of COPD-related moderate/SEV exacerbations in SEV and VSEV COPD patients were positively associated with poor HRQoL and work productivity and activity impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.